Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
CMPS
HOLDCOMPASS Pathways plc · Healthcare · United Kingdom · $1.5B · Avg Vol: $47M/d
COMPANY DESCRIPTION
COMPASS Pathways plc is a mental healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health, primarily focusing on psilocybin therapy for treatment-resistant depression. The company is at the forefront of researching and developing psilocybin as a regulated medicine, navigating complex regulatory pathways and clinical trials. Its leadership in this emerging therapeutic area provides a significant first-mover advantage and a distinct competitive position.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | 61.2M | — |
| EPS | — | -0.68 | -1.06 | -2.30 | -3.08 | — | -2.97 | — | — |
| Shares | — | 134.9M | 134.9M | 68.6M | 96.1M | -28.8% | — | — | — |
| Debt | — | 1.9M | 33.0M | 32.2M | 35.0M | 162.9% | 53.3M | — | — |
| Equity | — | 181.3M | 225.7M | 154.7M | -52.8M | -7.6% | — | — | — |
| Op CF | — | -105.5M | -97.4M | -119.2M | -157.2M | — | -159.5M | — | — |
| Inv CF | -0.3M | -0.6M | -64.0K | 0 | — | — | — | — | — |
| Fin CF | — | 1.0M | 173.8M | 63.8M | 140.7M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CMPS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CMPS | COMPASS Pathways plc(you) | $1.5B | 36 | HOLD |
| CVSG.L | CVS Group plc | $1.1B | 44 | HOLD |
| SPI.L | Spire Healthcare Group plc | $1.1B | 82 | STRONG BUY |
| OHGR.L | One Health Group Plc | $45M | 73 | BUY |
| IMCR | Immunocore Holdings plc | $1.8B | 48 | HOLD |
| ONT.L | Oxford Nanopore Technologies plc | $1.6B | 16 | STRONG SELL |
| SLN | Silence Therapeutics plc | $521M | 36 | HOLD |
| GNS.L | Genus plc | $1.9B | 54 | HOLD |
| OXB.L | Oxford Biomedica plc | $1.0B | 14 | STRONG SELL |
| AUTL | Autolus Therapeutics plc | $386M | 32 | SELL |
Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 56.9%